Good morning, everyone, and how are you today? We are doing just fine, despite an unusually busy start. To cope, we are quaffing multiple cups of stimulation to help us along. Perhaps you would like to join us. Remember, no prescription is required, which means there is no need to fuss with coupons or calculating copays and rebates. Meanwhile, here are a few items of interest to get you going. We hope your day is smashing and you conquer the world. And, as always, do keep in touch …

An anonymous donor is paying for a pricey Vertex Pharmaceuticals (VRTX) cystic fibrosis drug for a family whose insurance would not cover the cost for their 3-year-old daughter, The New York Post reports. The company had declined to provide a three-week supply of its Orkambi treatment, which the family could not afford. Justin Kennedy says his insurer refused to pay for the medicine, while the company says his daughter did not meet criteria for providing a so-called bridge supply. His wife’s insurance does not begin until Jan. 1, and he says they cannot afford the $20,000 cost until then.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy